Share on StockTwits

Biogen Idec (NASDAQ:BIIB) EVP Steven H. Holtzman unloaded 1,222 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $327.90, for a total value of $400,693.80. Following the transaction, the executive vice president now directly owns 9,412 shares in the company, valued at approximately $3,086,195. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Shares of Biogen Idec (NASDAQ:BIIB) opened at 328.45 on Thursday. Biogen Idec has a 52-week low of $160.42 and a 52-week high of $335.99. The stock has a 50-day moving average of $304.2 and a 200-day moving average of $259.7. The company has a market cap of $77.643 billion and a P/E ratio of 42.89.

Biogen Idec (NASDAQ:BIIB) last announced its earnings results on Wednesday, January 29th. The company reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.07. The company had revenue of $2.00 billion for the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the previous year, the company posted $1.40 earnings per share. The company’s revenue for the quarter was up 38.6% on a year-over-year basis. On average, analysts predict that Biogen Idec will post $11.35 earnings per share for the current fiscal year.

BIIB has been the subject of a number of recent research reports. Analysts at TheStreet reiterated a “buy” rating on shares of Biogen Idec in a research note on Tuesday. Finally, analysts at Zacks upgraded shares of Biogen Idec from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 4th. They now have a $375.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $301.00.

Biogen Idec Inc (NASDAQ:BIIB) is a global biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.